Ganirelix Acetate (Antagon/Orgalutran) - Complete Research Paper

1. Summary

Ganirelix acetate is a synthetic decapeptide GnRH (gonadotropin-releasing hormone) antagonist used to prevent premature ovulation in women undergoing controlled ovarian hyperstimulation for in vitro fertilization (IVF) and other assisted reproductive technologies (ART). Unlike GnRH agonists that initially stimulate and then desensitize pituitary receptors, ganirelix produces immediate, competitive blockade of GnRH receptors, providing rapid and reversible suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release.

FDA Approval: July 29, 1999 (Antagon by Organon Inc.) European Approval: May 17, 2000 (Orgalutran by N.V. Organon)

Ganirelix was the first GnRH antagonist approved in the United States for fertility treatment. The drug is administered as a daily subcutaneous injection of 0.25 mg, typically starting on day 5-7 of ovarian stimulation and continuing until hCG trigger administration. Its key advantages over traditional GnRH agonist protocols include shorter treatment duration, reduced gonadotropin requirements, lower risk of ovarian hyperstimulation syndrome (OHSS), and elimination of the initial "flare" effect. Ganirelix has demonstrated pregnancy rates comparable to GnRH agonist long protocols while offering improved patient convenience and cost-effectiveness.

Key Clinical Features:

• Indication: Prevention of premature LH surges during controlled ovarian hyperstimulation for IVF
• Administration: 0.25 mg subcutaneous injection once daily
• Treatment duration: Average 5.4 days (range 2-14 days)
• Bioavailability: >90% (exceptionally high for a peptide)
• Half-life: 13-16 hours
• Onset: Immediate suppression of LH/FSH (no flare effect)
• Reversibility: Rapid recovery upon discontinuation
• Generic availability: Yes (multiple manufacturers)

1a. Goal Archetype Integration

Primary Goal Archetype: GnRH Antagonist for Controlled Ovarian Hyperstimulation

Therapeutic Classification:

• Drug Class: Gonadotropin-releasing hormone (GnRH) antagonist
• Subclass: Synthetic decapeptide GnRH receptor blocker
• Primary Use Case: In vitro fertilization (IVF) and assisted reproductive technology (ART)

Goal Archetype Mapping:

User Intent Matching:

High-Priority Goals (Immediate Clinical Need):

• "I want to prevent premature ovulation during my IVF treatment to improve my chances of conception."
• "I need a way to control hormone surges during my assisted reproductive technology cycle to avoid complications."
• "I need a reliable way to time my hCG trigger shot for optimal egg retrieval in my IVF cycle."

Optimization Goals (Treatment Enhancement):

• "I'm looking to optimize my fertility treatment by ensuring multiple follicles develop for better egg retrieval."
• "I'm interested in reducing the risk of ovarian hyperstimulation syndrome while undergoing fertility treatments."
• "I want a fertility treatment that offers a shorter duration and more convenience compared to traditional methods."

Special Population Goals:

• "I'm seeking a medication that can help me manage my polycystic ovary syndrome (PCOS) during fertility treatments."
• "I need an IVF protocol suitable for my diminished ovarian reserve."
• "I want a protocol that minimizes medication burden while maintaining efficacy."

Archetype-Specific Considerations:

2. Mechanism of Action

Ganirelix is a third-generation GnRH antagonist with high antagonistic activity and minimal histamine-releasing properties—a significant improvement over earlier antagonists that caused problematic histamine reactions.

Primary Mechanism: Ganirelix competitively binds to GnRH receptors on pituitary gonadotroph cells without activating them. This competitive blockade prevents endogenous GnRH from stimulating the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The suppression is:

• Immediate: Occurs within hours of administration (no initial stimulation)
• Dose-dependent: Higher doses produce greater suppression
• Reversible: Pituitary function recovers rapidly after discontinuation

Receptor Binding Affinity: Ganirelix demonstrates significantly higher receptor binding affinity than native GnRH:

• Ganirelix Kd = 0.4 nM
• Native GnRH Kd = 3.6 nM

This 9-fold greater affinity allows ganirelix to effectively outcompete endogenous GnRH for receptor binding.

Structural Modifications: Ganirelix is a synthetic decapeptide modified from native GnRH at multiple positions:

• Position 1: D-Nal(2) substitution
• Position 2: D-Phe(4Cl) substitution
• Position 3: D-Pal(3) substitution
• Position 6: D-hArg(Et)2 substitution
• Position 8: hArg(Et)2 substitution
• Position 10: D-Ala-NH2 C-terminal modification

These modifications provide:

1. Enhanced receptor binding affinity
2. Resistance to enzymatic degradation
3. Prolonged half-life
4. Reduced histamine-releasing potential

Comparison with GnRH Agonists:

Clinical Relevance: In IVF protocols, preventing premature LH surges is critical because:

• Premature LH surge causes premature ovulation
• Eggs released prematurely are often too immature for fertilization
• Premature luteinization can compromise oocyte quality
• The "window" for optimal egg retrieval is narrow

3. FDA-Approved Indications

Primary Indication: Ganirelix acetate injection is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation.

Specific Use: The drug is used in conjunction with follicle-stimulating hormone (FSH) treatment during IVF and other assisted reproductive technology (ART) protocols to:

1. Prevent premature ovulation
2. Allow multiple follicle development
3. Enable optimal timing of hCG trigger
4. Facilitate scheduled egg retrieval

Regulatory Status:

Off-Label Uses (Not FDA-Approved): While not FDA-approved for these indications, ganirelix has been studied or used off-label for:

• Prevention of premature LH surge in ovulation induction (non-IVF)
• Male infertility protocols (experimental)
• Polycystic ovary syndrome (PCOS) management during ART

Note on Indication Scope: Ganirelix is specifically approved for fertility treatment in women undergoing controlled ovarian hyperstimulation. Unlike some other GnRH antagonists (e.g., degarelix), ganirelix is NOT approved for:

• Prostate cancer treatment
• Endometriosis
• Uterine fibroids
• Central precocious puberty
• Other hormone-dependent conditions

4. Dosing and Administration

Standard Dosing Protocol:

Initiation:

• Begin ganirelix 0.25 mg subcutaneous injection once daily
• Start during the early-to-mid follicular phase of the stimulation cycle
• Typical start: Day 5-7 of FSH stimulation (or when lead follicle reaches 12-14 mm)

Dose Selection Rationale: The 0.25 mg daily dose was selected after phase II studies demonstrated it was the minimal effective daily dose to prevent premature LH surges while yielding the highest ongoing pregnancy rate per started cycle.

Treatment Duration:

• Mean duration: 5.4 days
• Range: 2-14 days
• Continue until day of hCG administration

Administration Technique:

1. Administer by subcutaneous injection
2. Preferred injection sites: abdomen (around navel) or upper thigh
3. Rotate injection sites to minimize local reactions
4. Inject at approximately the same time each day
5. Pre-filled syringes are ready for use (no mixing required)

Critical Timing:

• The interval between ganirelix injections should not exceed 30 hours
• The interval between the last ganirelix injection and hCG trigger should not exceed 30 hours
• Exceeding these intervals may result in premature LH surge

Product Presentation:

• Pre-filled syringe: 250 mcg/0.5 mL
• Ready-to-use formulation (advantage over cetrorelix which requires reconstitution)
• Single-use, disposable

Dose Adjustments: No dose adjustments are required for:

• Mild to moderate renal impairment
• Mild hepatic impairment
• Age (within reproductive age range)
• Body weight (standard dose effective across typical range)

Special Considerations:

• If a dose is missed, administer as soon as remembered
• If close to next scheduled dose, do not double dose
• Contact physician if dose is missed near critical treatment phase

4a. Age-Stratified Dosing

Overview: While ganirelix dosing (0.25 mg daily) remains constant across age groups, protocol modifications and monitoring intensity vary significantly based on maternal age and ovarian reserve status. Age-related decline in ovarian function necessitates individualized treatment approaches.

Age-Based Protocol Considerations:

Ganirelix Initiation Timing by Age:

Dose Consistency Across Ages:

• Standard dose: 0.25 mg SC daily for ALL reproductive age groups
• No age-based dose reduction: Efficacy maintained across age spectrum
• No age-based dose increase: 0.25 mg provides adequate LH suppression regardless of age
• Duration variation: Older patients may have shorter stimulation cycles (fewer ganirelix doses)

Age-Related Ovarian Response Patterns:

AMH = Anti-Mullerian Hormone; AFC = Antral Follicle Count

Special Considerations by Age Group:

Young Women (<30):

• Higher OHSS risk with robust ovarian response
• Consider GnRH agonist trigger instead of hCG if >15-20 follicles
• May need coasting if estradiol exceeds 4,000 pg/mL
• Freeze-all strategy for OHSS prevention

Women 35-39 Years:

• Balance between adequate stimulation and premature LH surge prevention
• More frequent monitoring (every 1-2 days)
• Flexible antagonist start based on follicle development preferred
• May require higher FSH doses to achieve adequate response

Women ≥40 Years:

• Very close monitoring required
• Consider starting ganirelix earlier (day 4-5) due to faster follicular development
• Lower estradiol thresholds for trigger decision
• Reduced margin for error in timing

Clinical Pearls:

1. Ganirelix dose does NOT change with age—only protocol timing and monitoring intensity
2. Older women may have shorter treatment cycles overall
3. Advanced maternal age correlates with faster follicular development in some cases
4. Poor responders at any age may benefit from flexible antagonist initiation
5. Chronological age matters less than biological ovarian reserve (AMH, AFC)

5. Pharmacokinetics

Absorption: Ganirelix demonstrates exceptionally high bioavailability for a peptide drug:

• Absolute bioavailability: 91.3% ± 6.7% (>90%)
• Time to peak concentration (Tmax): 1.0-1.1 hours
• Peak concentration (Cmax) at 0.25 mg: 11.2 ng/mL (mean)

The rapid and complete absorption after subcutaneous injection allows for predictable pharmacodynamic effects.

Dose Proportionality: Pharmacokinetics are dose-proportional across the clinical dose range:

Distribution:

• Volume of distribution (Vd): 43.7 ± 11.4 L
• Protein binding: Approximately 81.9%

The moderate volume of distribution indicates distribution beyond plasma into peripheral tissues.

Metabolism:

• Primary: Hepatic metabolism via peptidases
• Secondary: Renal metabolism
• No active metabolites identified with clinical significance
• Does not significantly inhibit or induce CYP450 enzymes

Elimination:

• Elimination half-life: 12.8-16.2 hours (mean ~13-16 hours)
• Clearance: 2.4 L/hour
• Excretion routes:
  • Feces: ~75%
  • Urine: ~22%

Steady-State:

• Achieved within 2-3 days of daily dosing
• Steady-state concentrations are predictable based on dose

Pharmacokinetic Comparison (IV vs. SC):

The nearly identical pharmacokinetics between IV and SC administration confirm the high bioavailability of subcutaneous ganirelix.

Special Populations:

• Renal impairment: Limited data; caution advised in severe impairment
• Hepatic impairment: Limited data; caution advised in severe impairment
• Elderly: Not applicable (fertility indication)
• Pediatric: Not indicated

6. Side Effects and Adverse Reactions

Clinical Trial Data: Pooled data from three clinical trials involving 794 women undergoing IVF revealed the following adverse event profile:

Common Adverse Events (≥1% incidence):

*Fetal death rate reflects early pregnancy loss, which is inherent to the IVF population rather than drug-specific.

Injection Site Reactions: The most common localized adverse effect:

• Overall incidence: 12-20% report at least one reaction within 1 hour
• Moderate or severe reactions: 2% of treatment cycles
• Manifestations: Redness, bruising, pain, itching, swelling
• Duration: Generally resolve within 4 hours
• Clinical significance: Rarely treatment-limiting

Drug-Related Adverse Reactions: Adverse reactions attributed specifically to ganirelix (occurring in 2-3% of patients):

• Headache
• Malaise/fatigue
• Nausea

Phase I Study Data (Healthy Volunteers): In a 7-day dosing study with 0.125-0.5 mg doses:

*Note: Higher incidence in healthy volunteers may reflect more rigorous reporting and higher doses tested.

Serious Adverse Reactions:

Hypersensitivity Reactions:

• Anaphylaxis and anaphylactoid reactions reported (rare)
• Angioedema reported
• Cases have occurred with first dose
• Requires immediate medical attention

Ovarian Hyperstimulation Syndrome (OHSS):

• Incidence: 2.4% in clinical trials
• Caused by ovarian stimulation protocol, not ganirelix specifically
• Ganirelix protocols may actually reduce OHSS risk compared to GnRH agonist protocols
• Symptoms: Enlarged ovaries, abdominal pain/distension, fluid accumulation

Laboratory Abnormalities:

• Neutrophil count ≥8.3 × 10⁹/L observed in 11.9% of treated subjects
• Clinical significance unclear; generally asymptomatic

Congenital Malformations: Follow-up studies reported:

• Ganirelix group: 7.6%
• GnRH agonist comparison group: 5.5%
• Both rates fall within normal population incidence (3-7%)
• Current data do not suggest increased malformation risk

7. Drug Interactions

Clinically Significant Interactions:

Ganirelix has minimal documented drug interactions due to its specific mechanism of action and metabolic profile. Its peptide structure and receptor-specific activity limit systemic metabolic interference.

Pharmacokinetic Interactions:

• No significant CYP450 enzyme inhibition or induction
• Unlikely to alter metabolism of co-administered drugs
• No significant protein binding displacement interactions expected
• Metabolism via peptidases (not hepatic cytochrome system)

Pharmacodynamic Interactions:

Fertility Drug Protocol Interactions:

Intended Co-Administration (Required for IVF):

Contraindicated Combinations:

Medications Requiring Monitoring (Not Contraindicated):

Foods and Supplements:

No Known Interactions:

• No food interactions affecting absorption or efficacy
• No dietary restrictions required
• No grapefruit interaction (unlike many oral medications)

Supplements Commonly Used During IVF (No Interaction with Ganirelix):

Laboratory Test Interactions:

Timing Considerations with hCG Trigger:

Critical interaction timing:

• Last ganirelix injection must be within 30 hours of hCG trigger
• Exceeding 30-hour interval risks premature LH surge
• hCG trigger can be administered same day as last ganirelix (different injection sites)
• Egg retrieval occurs 34-36 hours post-hCG trigger

8. Contraindications

Absolute Contraindications:

1. Known hypersensitivity to ganirelix acetate or any component of the formulation
2. Known hypersensitivity to GnRH or any other GnRH analog
3. Known or suspected pregnancy - Pregnancy Category X
4. Lactation (breastfeeding)

Pregnancy Considerations:

• Ganirelix is absolutely contraindicated during pregnancy
• The drug interferes with hormone signaling essential for pregnancy maintenance
• No teratogenicity studies in pregnant humans
• Animal studies: fetal resorption at high doses

Mechanism of Pregnancy Harm: GnRH antagonists suppress gonadotropin release, which is critical for:

• Early pregnancy hormone support
• Corpus luteum function
• Progesterone production

Verification Before Use: Before starting ganirelix:

• Confirm patient is not pregnant (serum or urine β-hCG)
• Patient should use barrier contraception before starting ART cycle
• Counsel patient about pregnancy risks if drug exposure occurs

Relative Contraindications/Precautions:

1. Severe renal impairment: Limited pharmacokinetic data
2. Severe hepatic impairment: Limited pharmacokinetic data
3. History of severe allergic reactions: Increased risk of hypersensitivity
4. Latex allergy: Check syringe components (packaging may vary by manufacturer)

Not Contraindicated But Requiring Caution:

• Age >35 years (reduced ovarian response to stimulation)
• Low ovarian reserve
• Previous OHSS
• Polycystic ovary syndrome (PCOS)

9. Special Populations

Pregnancy (Category X):

• Absolutely contraindicated
• Discontinue immediately if pregnancy is suspected
• If inadvertent exposure occurs during early pregnancy, discontinue and monitor
• Limited human data on pregnancy outcomes after exposure

Lactation:

• Contraindicated during breastfeeding
• Unknown if ganirelix is excreted in human milk
• Given peptide nature, some excretion likely
• Risk to nursing infant cannot be excluded

Pediatric Use:

• Not indicated in children
• Safety and efficacy not established in pediatric population
• GnRH antagonists are used in children for central precocious puberty (different drugs—not ganirelix)

Geriatric Use:

• Not applicable—ganirelix is used for fertility treatment
• No studies in post-menopausal women

Renal Impairment:

• Mild-moderate: No dose adjustment required based on available data
• Severe: Use with caution; limited pharmacokinetic data
• Monitor for accumulation or increased adverse effects

Hepatic Impairment:

• Mild-moderate: No dose adjustment required based on available data
• Severe: Use with caution; limited pharmacokinetic data
• Hepatic metabolism contributes to clearance

Women with Low Ovarian Reserve:

• May have reduced response to stimulation
• Ganirelix dosing remains standard
• Requires careful monitoring of follicular development
• Earlier initiation may be considered in some protocols

Women with PCOS:

• Higher risk of OHSS with ovarian stimulation
• Ganirelix protocols may reduce OHSS risk compared to agonist protocols
• Close monitoring required
• Consider lower gonadotropin doses

Obesity:

• Standard dosing appears effective across typical weight ranges
• No formal dose-adjustment studies
• Monitor response to treatment

10. Monitoring Parameters

Pre-Treatment Monitoring:

During Treatment Monitoring:

Ultrasound Monitoring:

• Transvaginal ultrasound every 1-3 days during stimulation
• Assess follicle number and size
• Monitor for OHSS signs (ovarian enlargement, free fluid)
• Determine optimal timing for hCG trigger

Hormonal Monitoring:

Signs Requiring Intervention:

Premature LH Surge:

• LH >10 IU/L may indicate inadequate suppression
• Consider timing and compliance with ganirelix
• May require protocol adjustment

OHSS Risk Indicators:

• Estradiol >3,000-4,000 pg/mL

• 15-20 follicles

• Rapid estradiol rise
• May require "coasting" or GnRH agonist trigger

Injection Site Monitoring:

• Assess for local reactions
• Rotate sites if reactions occur
• Severe reactions may require evaluation

Post-Treatment:

• hCG trigger timing based on follicle maturity
• Egg retrieval typically 34-36 hours post-trigger
• Luteal phase support as per clinic protocol

11. Cost and Availability

Pricing (United States, 2024-2025):

Generic Availability: Ganirelix acetate is available as a generic medication:

• Original brand: Antagon (discontinued in US)
• Current brand: Fyremadel
• Generic manufacturers: Ferring Pharmaceuticals, Sun Pharmaceutical, Amphastar Pharmaceuticals
• Generic approval: Post-patent expiry (patents extended into late 2020s in some markets)

Insurance Coverage:

• Medicare Part D: Usually NOT covered (fertility medications typically excluded)
• Medicare Advantage: Usually NOT covered
• Private insurance: Variable coverage depending on fertility benefits
• State mandates: Some states require fertility coverage (IL, MA, CT, NJ, NY, etc.)
• Specialty pharmacy benefits: May have separate coverage tier

Cost Considerations:

• Ganirelix is a specialty medication requiring more steps to obtain
• Often purchased through specialty pharmacies or fertility clinic dispensaries
• Discount fertility medication vendors may offer significant savings
• Coupon programs (GoodRx, SingleCare) can reduce out-of-pocket costs substantially

Compared to Alternatives:

Ganirelix offers a cost advantage over cetrorelix, particularly when generic versions are available.

International Availability:

• United States: Fyremadel (brand), generic ganirelix
• European Union: Orgalutran, Fyremadel, generic ganirelix
• Canada: Orgalutran
• Australia: Orgalutran
• Widely available in most developed countries with ART services

Product Presentation:

• Pre-filled syringe: 250 mcg/0.5 mL
• Ready-to-use (no reconstitution required)
• Box typically contains single or multiple syringes

12. Clinical Evidence Summary

Pivotal Clinical Trials:

Phase III Registration Trials: Three clinical trials formed the basis for FDA approval:

• Total enrollment: 794 women undergoing IVF
• Demonstrated efficacy in preventing premature LH surges
• Pregnancy rates comparable to GnRH agonist protocols

Key Efficacy Findings:

Prevention of Premature LH Surge:

• Ganirelix effectively suppresses LH to prevent premature ovulation
• LH surge incidence with ganirelix: <10%
• Dose of 0.25 mg selected as minimal effective dose yielding highest pregnancy rates

Pregnancy Outcomes:

Comparative Study: Ganirelix vs. Triptorelin (GnRH agonist):

• Ongoing pregnancy rates equivalent (ganirelix 39.8% vs. triptorelin 39.2%)
• Lower twin pregnancy rate with ganirelix (22.2% vs. 44.7%)
• Lower OHSS risk with ganirelix protocols

Advantages of GnRH Antagonist Protocols: Prospective comparative studies demonstrated:

1. Immediate reversibility of drug effects
2. Less FSH required for adequate stimulation
3. Shorter stimulation duration (fewer days of injections)
4. Reduced OHSS incidence compared to long agonist protocols
5. Reduced patient burden (fewer injections, shorter treatment)
6. Lower medication costs overall

Safety in Offspring:

• Congenital malformation rate: 7.6% (within normal population range of 3-7%)
• No increase in ectopic pregnancy rate
• No increase in miscarriage rate compared to GnRH agonist protocols

Pharmacovigilance Data (2004-2024): 20-year post-marketing surveillance analysis confirms:

• Established safety profile maintained in real-world use
• Hypersensitivity reactions rare but reported
• Local injection site reactions remain most common adverse event

13. Comparison with Alternatives

GnRH Antagonist Comparison: Ganirelix vs. Cetrorelix

Key Differences:

• Convenience: Ganirelix comes pre-mixed (advantage for patient self-administration)
• LH control: Cetrorelix shows statistically superior LH suppression
• OHSS risk: Cetrorelix associated with lower OHSS incidence
• Cost: Ganirelix is more cost-effective
• Endometrial receptivity: Cetrorelix may offer advantages

Clinical Recommendations (from comparative studies):

• For high-risk OHSS patients: Cetrorelix may be preferable
• For rapid LH control needs: Either drug effective
• For cost-conscious patients: Ganirelix offers savings
• For first-time IVF: Either drug appropriate

GnRH Antagonist vs. GnRH Agonist Protocols:

When to Choose Ganirelix Over Alternatives:

1. Patient preference for fewer injections
2. Desire for shorter treatment duration
3. Cost considerations
4. Previous poor response to agonist protocols
5. High responders at risk for OHSS (antagonist protocols safer)
6. Need for rapid suppression without flare

14. Storage and Handling

Storage Conditions:

Temperature:

• Store at controlled room temperature: 20°C to 25°C (68°F to 77°F)
• Excursions permitted: 15°C to 30°C (59°F to 86°F)
• Do NOT freeze
• Do NOT refrigerate (room temperature storage is preferred)

Light Protection:

• Store in original packaging until use
• Protect from light
• Keep syringe in carton until ready to administer

Handling:

• Pre-filled syringe is single-use only
• Do not reuse needles or syringes
• Inspect visually before use
• Solution should be clear and colorless to slightly yellow
• Do not use if solution is cloudy, discolored, or contains particles

Disposal:

• Dispose of used syringes in FDA-cleared sharps disposal container
• Do not dispose in household trash
• Follow local regulations for medical waste disposal

Stability:

• Shelf life: Refer to expiration date on packaging (typically 2-3 years from manufacture)
• Do not use after expiration date
• Once removed from carton, use promptly

Travel Considerations:

• Can be transported at room temperature
• Protect from extreme temperatures
• Keep in original packaging during travel
• No refrigeration required (easier for travel than refrigerated medications)

Patient Education Points:

1. Store at room temperature—do NOT refrigerate
2. Keep in original carton until use
3. Check expiration date before each use
4. Visually inspect for particles or discoloration
5. Use proper sharps disposal

15. References

1. FDA Drug Approval Package: Antagon (Ganirelix Acetate) NDA# 21-057. Approved July 29, 1999. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21057_Antagon.cfm

2. Ganirelix Acetate Injection Prescribing Information. FDA Label 2024. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021057s024lbl.pdf

3. European Medicines Agency. Orgalutran EPAR Product Information. Available at: https://www.ema.europa.eu/en/documents/product-information/orgalutran-epar-product-information_en.pdf

4. DrugBank. Ganirelix: Uses, Interactions, Mechanism of Action. Available at: https://go.drugbank.com/drugs/DB06785

5. Wilcox J, Potter D, Moore M, Ferriani R, Mol BW. Prospective, randomized trial comparing cetrorelix acetate and ganirelix acetate in a programmed, flexible protocol for premature luteinizing hormone surge prevention in assisted reproductive technologies. Fertil Steril. 2005;84(1):108-117.

6. Oberyé J, Mannaerts B, Huisman J, Timmer C. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers. Fertil Steril. 1999;72(6):1001-1005.

7. Ganirelix and the prevention of premature luteinizing hormone surges. PMC 2023. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC10201301/

8. Post-marketing safety profile of ganirelix in women: a 20-year pharmacovigilance analysis of global adverse drug event databases (2004–2024). PMC 2024. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12016398/

9. Comparison of pregnancy outcomes and safety between cetrorelix and ganirelix in IVF/ICSI antagonist protocols: a retrospective cohort study. Front Reprod Health. 2025. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12034626/

10. Mayo Clinic. Ganirelix (subcutaneous route) - Side effects & dosage. Available at: https://www.mayoclinic.org/drugs-supplements/ganirelix-subcutaneous-route/description/drg-20064001

11. GoodRx. Ganirelix 2025 Prices, Coupons & Savings Tips. Available at: https://www.goodrx.com/ganirelix

12. Medscape. Antagon, Orgalutran (ganirelix) dosing, indications, interactions, adverse effects. Available at: https://reference.medscape.com/drug/ganirelix-342757

Document compiled from FDA prescribing information, peer-reviewed literature, and clinical practice guidelines. Last updated: December 2024.

Status: PAPER 66 OF 76 COMPLETE

Next Paper: #67 - Cetrorelix